These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 10489098)

  • 1. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of moxonidine in the treatment of hypertension.
    Prichard BN; Graham BR
    J Hypertens Suppl; 1997 Jan; 15(1):S47-55. PubMed ID: 9050986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats.
    Buccafusco JJ; Lapp CA; Westbrooks KL; Ernsberger P
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1162-71. PubMed ID: 7791087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites.
    Ernsberger P; Damon TH; Graff LM; Schäfer SG; Christen MO
    J Pharmacol Exp Ther; 1993 Jan; 264(1):172-82. PubMed ID: 8380858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruption of central neuronal pathway of imidazoline I1 receptor mediates the hypertensive effect of cyclosporine in rats.
    El-Mas MM; Omar AG; Helmy MM; Mohy El-Din MM
    Brain Res; 2009 Jan; 1248():96-106. PubMed ID: 19028461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
    Ziegler D; Haxhiu MA; Kaan EC; Papp JG; Ernsberger P
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S26-37. PubMed ID: 8872297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
    Bock C; Niederhoffer N; Szabo B
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biphasic dose-dependent modulation of cardiac parasympathetic activity by moxonidine, an imidazoline I1-receptor agonist.
    Turcani M
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):524-35. PubMed ID: 19034032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine.
    Chan CK; Burke SL; Zhu H; Piletz JE; Head GA
    Neuroscience; 2005; 132(4):991-1007. PubMed ID: 15857704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Ernsberger P; Friedman JE; Koletsky RJ
    J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
    Velliquette RA; Ernsberger P
    J Pharmacol Exp Ther; 2003 Aug; 306(2):646-57. PubMed ID: 12756274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of NMDA and AMPA/kainate receptors involved in cardiovascular inhibition produced by imidazoline-like drugs in anaesthetized rats.
    Wang LG; Zeng J; Yuan WJ; Su DF; Wang WZ
    Exp Physiol; 2007 Sep; 92(5):849-58. PubMed ID: 17573415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.